Cross-Sector entity
DAFNA Capital Management is most often covered alongside Avance Nerve Graft, which appears in 3 of these 3 stories. Coverage clusters in market-trends, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: Mar 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
DAFNA Capital Management is most often covered alongside Avance Nerve Graft, which appears in 3 of these 3 stories. Coverage clusters in market-trends, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention DAFNA Capital Management, all published on March 22, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DAFNA Capital Management. Shared-story counts are live from our verified record — not editorial picks.
DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Source: fool.com · Jonathan Ponciano (us)
